Analysis study of FDA Adverse Event Reporting System (FAERS) of association between colitis and immune checkpoint inhibitors
Latest Information Update: 18 Feb 2020
At a glance
- Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Colitis
- Focus Adverse reactions
Most Recent Events
- 18 Feb 2020 New trial record